H2020Индивидуална стипендия2018–2020

IPACBIS · Identifying preclinical Alzheimer´s disease in the community using a panel of biomarkers among individuals with Subjective Memory Complaints

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период: 2018-03-01 → 2020-02-29
Финансиране от ЕС: 158 122 €
Участници: 1
Схема: MSCA-IF-EF-RI

Линиите свързват координатора с партньорите.

Накратко на български

Биомаркерите, като дебелината на ретината и протеините в гръбначната течност, се използват за откриване на ранни признаци на Алцхаймер при хора със субективни оплаквания от паметта. Ранното идентифициране на рисковите групи помага за разработването на по-ефективни терапии.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Identifying preclinical Alzheimer´s disease in the community using a panel of biomarkers among individuals with Subjective Memory Complaints

The dementia epidemic is a growing socio-economical problem in developed countries, including those in Europe, mainly due to the ageing population. Alzheimer´s disease (AD), the leading cause of dementia, has currently no prevention or cure. Identifying AD at early stages will likely improve the chances of developing an effective therapy. AD-related changes can be detected in brains of healthy individuals many years before the onset of cognitive decline using biomarkers such as lumbar puncture, magnetic resonance of the brain (MRI) or positron emission tomography (PET) with tracers against amyloid and tau proteins. Testing all elderly healthy individuals in the community would not be feasible neither cost-effective, but interestingly many of them experience Subjective Cognitive Decline (SCD) although show preserved cognition when tested. Although conditions such as drugs, depression, anxiety or lack of sleep may be the underlying cause of SCD, a small percentage of individuals with SCD are in fact experiencing the very initial symptoms of AD. The general aim of the IPACBIS project was to identify which subgroup of individuals with SCD is at risk of developing AD dementia in the future. For that, 200 individuals with SCD from the Fundació ACE Healthy Brain Initiative (FACEHBI) cohort were followed-up yearly during 2y and tested with positron emission tomography with Florbetaben (FBB, a tracer against the amyloid protein), lumbar puncture, optical coherence tomography (OCT) and very sensitive neuropsychological tests at the Fundació ACE in Barcelona, Spain. Specifically, we checked whether retinal thickness measured by OCT at baseline predicted PET-FBB positivity, cognitive worsening and conversion to Mild Cognitive Impairment (MCI) after a 2y follow-up. We additionally investigated the differences in visual care received among individuals with SCD, MCI and dementia evaluated at Fundació ACE Memory Clinic with OCT.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

The dementia epidemic is a growing socio-economical problem in developed countries, including Europe, mainly due to aged population. Alzheimer´s disease (AD), the leading cause of dementia, has currently no prevention or cure. Identifying AD at early stages will likely improve the chances of developing an effective therapy. AD-related changes can be detected in brains of healthy individuals many years before the onset of cognitive decline using biomarkers. Testing all elderly healthy individuals would not be cost-effective, but interestingly many of them experience subjective memory complaints (SMC) but show preserved cognition when tested. Although conditions such as drugs, depression, anxiety or lack of sleep may be the underlying cause of SMC, a small percentage of individuals with SMC are experiencing the very initial symptoms of AD. The aim of this proposal is to identify which subgroup of individuals with SMC is at risk of developing AD dementia in the future. 200 individuals with SMC will be followed-up for 2y and tested with positron emission tomography with Florbetaben, plasma, lumbar puncture, optical coherence tomography and very sensitive neuropsychological tests at the Fundació ACE in Barcelona. Those finally classified as preclinical AD due to positive biomarkers at baseline and cognitive impairment at follow-up will be offered to join clinical trials for disease-modifying therapies against AD. The MSCA fellowship will allow the researcher to establish an independent career back in Europe after a stay in the United States, start academic tenure-track, improve her publication record, and receive specialized training in novel biomarker techniques and the preclinical phase of AD. The host organization will benefit from the researcher´s knowledge in tau imaging and neuropathology and her international connections to establish new collaborative projects. Plans for communication, exploitation and dissemination of the results will be established.

Оригинален текст от CORDIS (на английски).

Участници

FUNDACIO ACE · BarcelonaКоординаторИспания